AU703793B2 - Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) - Google Patents

Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) Download PDF

Info

Publication number
AU703793B2
AU703793B2 AU18962/95A AU1896295A AU703793B2 AU 703793 B2 AU703793 B2 AU 703793B2 AU 18962/95 A AU18962/95 A AU 18962/95A AU 1896295 A AU1896295 A AU 1896295A AU 703793 B2 AU703793 B2 AU 703793B2
Authority
AU
Australia
Prior art keywords
adenovirus
bdnf
cell
promoter
dna sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU18962/95A
Other languages
English (en)
Other versions
AU1896295A (en
Inventor
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Laurent Pradier
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU1896295A publication Critical patent/AU1896295A/en
Application granted granted Critical
Publication of AU703793B2 publication Critical patent/AU703793B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU18962/95A 1994-03-18 1995-03-02 Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) Ceased AU703793B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9403191A FR2717496B1 (fr) 1994-03-18 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.
FR9403191 1994-03-18
PCT/FR1995/000250 WO1995025804A1 (fr) 1994-03-18 1995-03-02 Adenovirus recombinants codant pour le facteur neurotrophique derive du cerveau (bdnf)

Publications (2)

Publication Number Publication Date
AU1896295A AU1896295A (en) 1995-10-09
AU703793B2 true AU703793B2 (en) 1999-04-01

Family

ID=9461190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18962/95A Ceased AU703793B2 (en) 1994-03-18 1995-03-02 Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)

Country Status (12)

Country Link
EP (1) EP0750676A1 (es)
JP (1) JPH09510358A (es)
KR (1) KR970701784A (es)
AU (1) AU703793B2 (es)
CA (1) CA2184200A1 (es)
FI (1) FI963674A0 (es)
FR (1) FR2717496B1 (es)
IL (1) IL112992A0 (es)
MX (1) MX9603490A (es)
NO (1) NO963559L (es)
WO (1) WO1995025804A1 (es)
ZA (1) ZA952244B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162942A1 (en) * 2018-02-20 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
DE60137414D1 (de) * 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755682A1 (en) * 1991-07-10 1997-01-29 Regeneron Pharmaceuticals, Inc. Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162942A1 (en) * 2018-02-20 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

Also Published As

Publication number Publication date
ZA952244B (en) 1996-01-16
FI963674A (fi) 1996-09-17
FR2717496B1 (fr) 1996-04-12
AU1896295A (en) 1995-10-09
FI963674A0 (fi) 1996-09-17
WO1995025804A1 (fr) 1995-09-28
EP0750676A1 (fr) 1997-01-02
MX9603490A (es) 1997-03-29
FR2717496A1 (fr) 1995-09-22
IL112992A0 (en) 1995-06-29
JPH09510358A (ja) 1997-10-21
CA2184200A1 (fr) 1995-09-28
KR970701784A (ko) 1997-04-12
NO963559L (no) 1996-08-26

Similar Documents

Publication Publication Date Title
US6245330B1 (en) Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)
US6685934B1 (en) Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)
AU712775B2 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
JP3487597B2 (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
JP2761513B2 (ja) 組換え繊維芽細胞成長因子
KR100242093B1 (ko) 신경교 유도 신경 영양성 인자
US20050244381A1 (en) Adenovirus including a gene coding for a superoxide dismutase
AU710727B2 (en) Adenovirus comprising a gene coding for glutathion peroxidase
US20040224409A1 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
EP0989859B1 (en) Cns neuroregenerative compositions and methods of use
KR20010015915A (ko) 증강된 유전자 송달을 위한 핵산과 혈관작용제의 조합
AU703793B2 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
IL112993A (en) Recombinant viruses, their preparation and their use in gene therapy
US20020031493A1 (en) Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
KR20010029506A (ko) 근위축성 측색 경화증 치료방법
US20020028212A1 (en) Recombinant viruses coding for a glutamate decarboxylase (gad) activity
HUT56881A (en) Process for expressing human nerve growth factor in arthropoda frugiperda cells infected with recombinant baculovirus
JP2007077125A (ja) 脊髄損傷治療剤
WO1994019462A1 (fr) Facteurs de croissance de la famille de l'harp, procede d'obtention et applications
JPH09509059A (ja) アルツハイマー病の動物モデル、調製方法および使用
MXPA96004024A (es) Virus recombinante, preparacion y utilizacion en terapia gen
JPH09510356A (ja) 神経膠細胞成熟因子ベータ型（ＧＭＦ−β）のための組み換えアデノウィルス
RU2321631C2 (ru) Неинфекционный для человека аденовирус как вектор для заместительной генной терапии нарушений ангиогенеза, обеспечивающий эффективный синтез ангиогенина человека в трансфецированных клетках млекопитающих, способ индукции ангиогенеза, способ лечения ишемической болезни, композиция для индукции ангиогенеза и лечения ишемической болезни
MXPA99000533A (es) Composicion farmaceutica para el tratamiento de la esclerosis lateral amiotrofica